Cases & Deals

Franklin Templeton invests in Edge Therapeutics

Clients Franklin Templeton

Jones Day advised Franklin Templeton in connection with its purchase of Series C-2 Convertible Preferred Stock in a private placement by Edge Therapeutics, Inc., a clinical-stage biotechnology company that discovers, develops, and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.